This roundtable series covers tyrosine kinase inhibition in the first line for patients with hepatocellular carcinoma discussed in virtual live events.
Interpreting Results From New and Previous Trials of Lenvatinib in HCC
October 26th 2022During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCC
November 9th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
Physicians Discuss Their Impressions of Recent IO/TKI Trials for HCC
February 6th 2023During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.
Determining Need for Biopsy in Suspected Hepatocellular Carcinoma
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.